Is Carboplatin needed for the neoadjuvant treatment of HER2 positive Breast cancer?
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a recent by Xiu-Chun Chen on X:
“Is carboplatin needed for the neoadjuvant treatment of HER2 positive Breast cancer?
The HELEN006 phase 3 trial randomized patients to TCHPx6 vs NabTHPx6.
NabTHP had significantly higher pCR rate vs TCHP (66% vs 57%), with less toxicities. Compass HER-pCR trial ongoing to validate THP (x4).”
Authors: Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, Cheng-Zheng Wang, Xian-Fu Sun, Zhen-Duo Lu, Lian-Fang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Ming-De Ma, Jennifer K Plichta, You-Wen He and Zhen-Zhen Liu
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
More posts featuring Paolo Tarantino.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023